TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03687073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indole-3-Carbinol
Description: Cohorts 2, 3, \& 4: 400 mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indole-3-Carbinol
Description: Cohorts 2, 3, \& 4: 400 mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indole-3-Carbinol
Description: Cohorts 2, 3, \& 4: 400 mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indole-3-Carbinol
Description: Cohorts 2, 3, \& 4: 400 mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silibinin
Description: Cohorts 1 \& 4: 720mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silibinin
Description: Cohorts 1 \& 4: 720mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silibinin
Description: Cohorts 1 \& 4: 720mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silibinin
Description: Cohorts 1 \& 4: 720mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silibin
Description: Cohort 3: 360mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silibin
Description: Cohort 3: 360mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silibin
Description: Cohort 3: 360mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silibin
Description: Cohort 3: 360mg
Study: NCT02067195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride)
Description: No hydration for patients without chronic kidney disease(CrCl\<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride)
Description: Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP \<13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and \>1.5 ml/kg/hr for LVEDP \>18 mmHg, whereas,0.5 ml/kg/hr for LVEDP \>20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
Study: NCT02513849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Daily tamoxifen tablet for approximately 4 weeks
Study: NCT04315194

Intervention type: DRUG
Intervention: clarithromycin-naproxen-oseltamivir
Description: to compare the safety and efficacy of clarithromycin-naproxen-oseltamivir combination therapy to that of oseltamivir treatment alone for hospitalised paediatric influenza patients.
Study: NCT01829971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX34
Description: micro RNA therapy
Study: NCT02602912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injeq Bioimpedance Probe (BIP) Needle
Description: Injeq Bioimpedance Probe (BIP) Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
Study: NCT04190979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medyria TrackCath System
Description: The TrackCath System is a non-implantable device and consists of the TrackCath Catheter and the TrackCath Equipment. It is designed to support the successful positioning of third-party guidewires and catheters in the arterial vasculature to detect and cannulate side branches during endovascular aneurysm repair procedures through the measurement of real-time blood flow velocity changes.
Study: NCT06089148

Intervention type: DIAGNOSTIC_TEST
Intervention: contrast enhanced digital mammography, tomosyntheis and MRI
Study: NCT03524885

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short implant placement
Description: Ten patients will be randomly selected for the short implants option, 2 or 3 implant 4-5 mm length and 4 mm diameter (Syra Short, Sweden \& Martina, Padua, Italy) will be positioned. The healing cap will be immediately connected and a vycril suture will be done after soft tissue reflection.~After three months an acrylic screw-retained bridge will be delivered. After further three months, a definitive restauration with a metal ceramic bridge will be seated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone regeneration with longer implants
Description: Ten patients will be randomly assigned to the regenerative group, 2 or 3 implant from 10 to 13 mm length intentionally exposed putting the implant platform 2 or 3 mm apical to CEJ of the adjacent tooth will be inserted.~A horizontal and vertical regeneration following GBR technique will be performed using not-resorbable PTFE titanium reinforced membrane (Cytoplast Osteogenics, US) fixed by titanium pins or miniscrews to ensure the perfect stability (Pro-fix, Cytoplast Osteogenics, US).
Study: NCT02453373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThermoSuit Cooling Induction
Description: Rapid induction of therapeutic hypothermia (32-34 degrees C) using the Life Recovery Systems ThermoSuit System

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium sulfate will be administered intravenously as needed to control shivering

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tPA
Description: tPA will be administered intravenously if indicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurothrombectomy
Description: If indicated, neurothrombectomy will be performed using an FDA-cleared device within the FDA-cleared treatment window.
Study: NCT02447055

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Study: NCT03105167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cortical bone trajectory screws
Description: cortical bone trajectory screws fixation takes the place of traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pedicle screws
Description: traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.
Study: NCT02453490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed-based chemotherapy
Description: Raltitrexed: 2.0mg,iv,15min,d1,Oxaliplatin:85mg/m2 iv,d1, q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed-based chemotherapy
Description: Raltitrexed: 2.0mg,iv,15min,d1,Irinotecan:180mg/m2 iv,d1, q2w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil-based chemotherapy
Description: 5-fluorouracil:400mg/m2,ivp,2h,d1,1200mg/m2/d\*2d(2400mg/m2,iv46-48h); Oxaliplatin:85mg/m2 iv,d1,q2w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil-based chemotherapy
Description: 5-fluorouracil: 400mg/m2,ivp,2h,d1,1200mg/m2/d\*2d(2400mg/m2,iv46-48h); Irinotecan:180mg/m2 d1, iv,q2w
Study: NCT03598647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect and physical activity
Description: The focus of this intervention is to help the participant to become more aware of their positive feelings and experiences related to exercise. They will learn about typical affective responses to exercise, view their own affective responses to exercise, and they will be taught cognitive strategies for altering affective responses to exercise. Participants will also receive general information about exercise safety, physical activity guidelines, and exercise intensity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity information
Description: Participants will receive general information about exercise safety, physical activity guidelines, and exercise intensity.
Study: NCT00688155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Training
Description: Two 1-hour center and two 15- to 45-minute home-based training sessions per week to include aerobic, strength, flexibility, and balance training for 6 months. The ultimate goal is to accumulate 150 minutes of walking per week between center and home-based sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Training
Description: Two 1-hour center and two 15- to 45-minute home-based training sessions per week to include aerobic, strength, flexibility, and balance training for 6 months. The ultimate goal is to accumulate 150 minutes of walking per week between center and home-based sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Two 1-hour sessions per week for the first two months and then one 1-hour session per week for months 3-6.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Two 1-hour sessions per week for the first two months and then one 1-hour session per week for months 3-6.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Aging Education
Description: One 1-hour lecture each week for 3 months, then monthly.
Study: NCT01971021

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICC or subcutaneous venous port

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICC or subcutaneous venous port
Study: NCT01496729

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane (TAP) block
Description: A Transversus abdominis plane (TAP) block with ropivacaine, a local anesthetic, will be performed at the end of the surgical procedure.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham TAP block with normal saline
Description: A sham TAP block with normal saline will be performed at the end of the surgical procedure.
Study: NCT02905929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActivPAL inclinometer
Description: Participants will wear a thigh-worn inclinometer for the first 3 weeks of the intervention, and at the mid-point of the intervention. The device will monitor their sitting and standing time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone counseling call: Breaking up sitting time
Description: Participants will receive 5 counseling phone calls to check-in on goal setting, strategies, and tools.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person counseling: Breaking up sitting time
Description: Participants will receive 3 in-person health education sessions. At these sessions participants will receive feedback from the ActivPAL showing periods throughout the day where participants have been sitting. Participants will also develop action plans, check-in on goal setting, and use of tools at these sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone counseling call: Healthy living
Description: Participants will receive a healthy living educational intervention over the phone, developed and tested by the investigators in previous studies. Participants will not receive any information on diet, physical activity or sedentary behavior that may affect the outcomes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tools to prompt standing
Description: Investigators will provide standing desks to participants who spend time sitting at a computer. Additional tools to help prompt standing are mechanical and electronic timers set to interrupt long periods of sitting and cues in the environment such as standing during commercial breaks and phone calls.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person counseling: Healthy living
Description: Control subjects will receive one in-person counseling session about healthy living. Participants will not receive any information on diet, physical activity or sedentary behavior that may affect the outcomes.
Study: NCT03631030

Intervention type: DEVICE
Group type: OTHER
Intervention: Cooled radiofrequency ablation
Description: Cooled Radiofrequency ablation (CRFA) is a well-established method for delivering lesions into nervous tissue to accomplish neurotomy procedures
Study: NCT04334707

Intervention type: PROCEDURE
Intervention: Kidney Biopsy
Description: A kidney biopsy is a procedure that involves taking a small piece of kidney tissue for examination with a microscope. A licensed health care provider will perform a kidney biopsy.

Intervention type: PROCEDURE
Intervention: Kidney Biopsy
Description: A kidney biopsy is a procedure that involves taking a small piece of kidney tissue for examination with a microscope. A licensed health care provider will perform a kidney biopsy.
Study: NCT02484833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Study: NCT02098512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab Vedotin will be administered every 21 days starting on or around Day +42 post allogeneic stem cell transplant for a TOTAL of 4 doses as outlined below:~* 42 (+/-7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~* 63 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~* 84 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max = 180 mg) IV x 1~* 105 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplantation
Description: Following conditioning with chemotherapy, patients will receive stem cells from a matched related or unrelated donor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Intensity Conditioning
Description: Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide
Study: NCT04266184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape (KT)
Description: For abdominal taping, four I-shaped tapes will be used. Two of them will start from the superior symphisis pubis, follow the rectus abdominis muscle, and finish at the xiphoid process. Other two I-shaped tapes will start from the mid-symphisis pubis, follow the external oblique abdominals, and finish at the spina iliaca anterior superiors.~Symphisis pubis taping will be applied with two I-shaped tapes, by forming a X shape.~For lumbopelvic taping, three I-shaped KTs will be used. Two tapes will be applied bilaterally and longitudinally on the lumbar erector spinal muscles. The third tape will start from one sacroiliac joint and end at the other, vertically to the previous two tapes, forming a H-shape.~All tapings will be applied with 15-25% tension (tape-off tension). KTs will stay three days. They will be removed from the site, and the skin will be checked and cleaned. Then, they will be reapplied for the next three days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic belt (PB)
Description: The women in this group will use the belts, after adjusting them at a comfortable tension, after getting up the bed in the mornings, during daily activities and walking. Evaluation will be made three days after the first application and they will be asked to continue using it for the second three-day period.

Intervention type: OTHER
Group type: OTHER
Intervention: Educational program
Description: This program will include pain neuroscience education and ergonomic education, and will approximately last one hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program
Description: This program will include pain neuroscience education and ergonomic education, and will approximately last one hour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational program
Description: This program will include pain neuroscience education and ergonomic education, and will approximately last one hour.
Study: NCT00068575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa
Description: 3 million units subcutaneously every other day (Monday, Wednesday and Friday) during Days 1-19 and 29-45, for 6 1/2 weeks totaling 17 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 30 mg/m\^2 IV over 60 minutes on days 1, 8, 15, 29, 36, 43 - weekly for total 6 doses, during 5 1/2 weeks radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 175 mg/m\^2/day continuous infusion over 6 1/2 weeks for total 3 courses: Days 1-19 and 29-45, Days 71-108 and Days 127-168.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: External beam radiation on days 1-19 and days 29-45, 9 day treatment break on day 20.
Study: NCT02705924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: Participants will attend conferences where experts present the state of the art in various domains:~* Latest knowledge in oncogenetics~* Recommendations and morbidity of prophylactic breast surgeries and annexectomy~* Epidemiology of HBOC and comparative mortality risks with other syndromes/life habits~* How to perform the periodic breast screening~* Assisted medical procreation and embryo selection~* Importance of nutrition and physical activity as risk modulator~* Life habits: how one can increase or lower the cancer risk (tobacco, alcohol...)?~* Description of the assistance program (GENAUV) to help counselees exposed to a high cancer risk follow their medical screening.~The remaining time after this information, i.e. about half of the week-end, will comprise group activities, in particular role games (Moreno psychodrama approach) and group sharing under the supervision of a psychotherapist.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychoeducation
Description: Participants will attend conferences where experts present the state of the art in various domains:~* Latest knowledge in oncogenetics~* Recommendations and morbidity of prophylactic breast surgeries and annexectomy~* Epidemiology of HBOC and comparative mortality risks with other syndromes/life habits~* How to perform the periodic breast screening~* Assisted medical procreation and embryo selection~* Importance of nutrition and physical activity as risk modulator~* Life habits: how one can increase or lower the cancer risk (tobacco, alcohol...)?~* Description of the assistance program (GENAUV) to help counselees exposed to a high cancer risk follow their medical screening.~The remaining time after this information, i.e. about half of the week-end, will comprise group activities, in particular role games (Moreno psychodrama approach) and group sharing under the supervision of a psychotherapist.
Study: NCT04076514

Intervention type: PROCEDURE
Intervention: central neck dissection
Description: dissection of central cervical lymph node grope in low grade papillary thyroid cancer
Study: NCT00498160

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enriched Hematopoietic Stem Cell Infusion
Description: Enriched Hematopoietic Stem Cell Infusion
Study: NCT01839396

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation
Description: The Vercise™ DBS system will be implanted in subjects in both study arms. Stimulation parameters will vary depending on the study arm assignment. All subjects will receive therapeutic settings at the end of the blinded period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: The Vercise™ DBS system will be implanted in subjects in both study arms. Stimulation parameters will vary depending on the study arm assignment. All subjects will receive therapeutic settings at the end of the blinded period.
Study: NCT00021151

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Study: NCT03600064

Intervention type: DRUG
Group type: OTHER
Intervention: Misoprostol
Description: the women will be received two tablets of misoprostol 400 mcg vaginally before IUD removal (Misotac®; Sigma Pharma, SAE, Egypt).
Study: NCT01519596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Receive lifestyle-related counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Undergo physical activity intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive educational materials

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up care
Description: Undergo usual care
Study: NCT03129451

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome specimens in stool
Description: Analyzing Microbiome specimens in stool

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome specimens in stool
Description: Analyzing Microbiome specimens in stool

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome specimens in stool
Description: Analyzing Microbiome specimens in stool

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome specimens in stool
Description: Analyzing Microbiome specimens in stool

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome specimens in stool
Description: Analyzing Microbiome specimens in stool

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome specimens in stool
Description: Analyzing Microbiome specimens in stool

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome specimens in stool
Description: Analyzing Microbiome specimens in stool